Kim N Chi


Affiliation: British Columbia
Country: Canada


  1. Azad A, Volik S, Wyatt A, Haegert A, Le Bihan S, Bell R, et al. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015;21:2315-24 pubmed publisher
    ..Our data illustrate that genomic analysis of cfDNA is a minimally invasive method for interrogating mechanisms of therapeutic resistance in mCRPC. ..
  2. Khalaf D, Sunderland K, Eigl B, Kollmannsberger C, Ivanov N, Finch D, et al. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. Eur Urol. 2018;: pubmed publisher
    ..We found that elderly patients treated with abiraterone had better quality of life over time, with no difference between treatments for the younger subgroup of patients. ..
  3. request reprint
    Chi K, Ellard S, Hotte S, Czaykowski P, Moore M, Ruether J, et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol. 2008;19:746-51 pubmed
    ..The declines in PSA observed on treatment discontinuation indicate an effect on PSA production/secretion. Further study may be warranted but needs to consider the limitations of PSA as an indicator of progression and response. ..
  4. Chi K, Bjartell A, Dearnaley D, Saad F, Schroder F, Sternberg C, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol. 2009;56:594-605 pubmed publisher
    ..A number of new agents targeting mechanisms of PCa progression with early promising results are in clinical trials and have the potential to provide novel treatment options for CRPC in the near future. ..
  5. request reprint
    Chi K, Eisenhauer E, Fazli L, Jones E, Goldenberg S, Powers J, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005;97:1287-96 pubmed
    ..001 and Ptrend = .01, respectively). OGX-011 is well tolerated and reduces clusterin expression in primary prostate tumors. The optimal biologic dose for OGX-011 at the schedule used is 640 mg. ..
  6. Chi K, Hotte S, Yu E, Tu D, Eigl B, Tannock I, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:4247-54 pubmed publisher
    ..50; 95% CI, 0.29 to 0.87). Treatment with OGX-011 and docetaxel was well tolerated with evidence of biologic effect and was associated with improved survival. Further evaluation is warranted. ..
  7. Azad A, Eigl B, Murray R, Kollmannsberger C, Chi K. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol. 2015;67:23-29 pubmed publisher
    ..These results suggest that earlier treatment with docetaxel does not have a large impact on the activity of enzalutamide after abiraterone. ..
  8. Leibowitz Amit R, Pintilie M, Khoja L, Azad A, Berger R, Laird A, et al. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial. J Transl Med. 2016;14:12 pubmed publisher
    ..The observed alterations in several biomarkers during treatment with cabozantinib may provide insights on the effects of cabozantinib on tumor cells and on tumor micro-environment and may help point to potential co-targeting approaches. ..
  9. Lallous N, Volik S, Awrey S, Leblanc E, Tse R, Murillo J, et al. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol. 2016;17:10 pubmed publisher

More Information


  1. Chi K, Yu E, Jacobs C, Bazov J, Kollmannsberger C, Higano C, et al. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. Ann Oncol. 2016;27:1116-22 pubmed publisher
    ..Apatorsen was tolerated at the highest dose evaluated (1000 mg). Single-agent activity was suggested by changes in tumor markers, CTC, and stable measurable disease. Phase II studies evaluating apatorsen are underway. NCT00487786. ..
  2. Todenhöfer T, Azad A, Stewart C, Gao J, Eigl B, Gleave M, et al. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. J Urol. 2017;197:135-142 pubmed publisher
    ..These results reinforce the potential usefulness of AR-V7 as a prognostic and predictive biomarker for metastatic castration resistant prostate cancer. ..
  3. Chi K, Protheroe A, Rodriguez AntolĂ­n A, Facchini G, Suttman H, Matsubara N, et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol. 2018;19:194-206 pubmed publisher
    ..Janssen Research & Development. ..
  4. Chi K, Siu L, Hirte H, Hotte S, Knox J, Kollmansberger C, et al. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res. 2008;14:833-9 pubmed publisher
    ..OGX-011 can be given at a biologically effective dose with standard doses of docetaxel. Phase II trials of combined OGX-011 and chemotherapy are ongoing in patients with prostate, breast, and lung cancers. ..
  5. Chi K, Kheoh T, Ryan C, Molina A, Bellmunt J, Vogelzang N, et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2016;27:454-60 pubmed publisher
    ..Prognostic stratification with this model could assist clinical practice decisions for follow-up and monitoring, and may aid in clinical trial design. NCT00638690. ..
  6. Chi K, Higano C, Blumenstein B, Ferrero J, Reeves J, Feyerabend S, et al. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2017;18:473-485 pubmed publisher
    ..OncoGenex Technologies. ..
  7. Yu E, Ellard S, Hotte S, Gingerich J, Joshua A, Gleave M, et al. A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. Invest New Drugs. 2018;36:278-287 pubmed publisher
    ..Further evaluation of Hsp27 targeting in prostate cancer is warranted. ..